Nine years after the launch of its biosimilar rituximab in India, Dr Reddy's Laboratories (DRL) claims a tenfold increase in the number of patients treated with the monoclonal antibody. M V Ramana, DRL's executive vice president and head branded markets (India and emerging countries) tells Scrip about his plans for the product in Russia and elsewhere and the firm's thrust on delivering care beyond the pill.
Dr. Reddy's Laboratories Ltd.'s rituximab, a biosimilar version of Roche's monoclonal antibody MabThera/Rituxan, has made significant inroads in markets like India and Ukraine; approvals are also in place in Venezuela and Russia - all eyes are on a Russian tender for the product anticipated in November this year.
Dr Reddy's executive vice president and head branded markets (India and emerging countries), M V Ramana, said that the product was being sold in around 10 countries and plans
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.
The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.
